Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
14.4.2021 16:00:00 EEST | Business Wire | Press release
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer.
The collaboration, launched in 2019, has successfully combined MD Anderson’s innovative clinical research infrastructure and the patient-driven drug development capabilities of the Therapeutics Discovery division with Boehringer Ingelheim’s pipeline of innovative cancer medicines and expertise in advancing breakthrough therapies. Under the new agreement, joint research will continue for five additional years.
“Our collaboration with MD Anderson strengthens our determination to find solutions for the most difficult-to-treat cancers, and this latest commitment marks an important step forward, especially in our holistic KRAS program,” said Norbert Kraut, Ph.D., Head of Global Cancer Research at Boehringer Ingelheim. “We are delighted to extend our collaboration with MD Anderson. With our shared dedication to patients and like-minded approach to innovation, we have the potential to bring the medicines to lung and gastrointestinal cancer patients that they so much need.”
The flexible nature of the VRDC agreement allows the teams to expand their lung cancer indication programs targeting KRAS and TRAILR2, including Boehringer Ingelheim’s first-in-class SOS1::pan-KRAS inhibitor (BI 1701963), inhibitors of KRAS G12C (BI 1823911) and MEK (BI 3011441), as well as a novel undisclosed bi-specific TRAILR2 agonist.
The collaboration already has resulted in a number of joint publications, conference presentations (including at the 2021 AACR Annual Meeting) and clinical trial activities. Boehringer Ingelheim is pursuing a comprehensive mutant KRAS-directed effort with multiple programs expected to enter the VRDC with MD Anderson.
“We are proud to expand our work with Boehringer Ingelheim in a very exciting drug-development space – advancing novel targeted therapies against KRAS and TRAILR2,” said Timothy Heffernan, Ph.D., Head of Oncology Research in Therapeutics Discovery at MD Anderson. “Our collaboration is built upon a strong working relationship and complementary expertise, highlighting how an academic center and a pharmaceutical company can strategically work together to advance innovative therapies for patients with cancer.”
MD Anderson’s Therapeutics Discovery division is anchored by an experienced team of drug development experts working to advance the next generation of cancer therapies. The Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, led by Heffernan, performs cutting-edge translational research to rapidly advance new therapies to the patients most likely to benefit.
KRAS is the most frequently mutated cancer-causing oncogene. One in seven of all human metastatic cancers expresses KRAS mutations, with mutation rates of more than 30 percent in lung adenocarcinomas, more than 40 percent in colorectal cancers and more than 90 percent in pancreatic cancers. No approved treatments for KRAS-driven cancers exist currently, further underscoring the need for continued investment in research and development. Tumor cell-selective activation of TRAILR2 can trigger cancer cell death in indications of high medical need, including lung and gastrointestinal malignancies.
Intended Audiences
This press release is issued from our corporate headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Disclosures
MD Anderson has an institutional financial conflict of interest with Boehringer Ingelheim related to this research and has therefore implemented an Institutional Conflict of Interest Management and Monitoring Plan.
Please click on the following link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/expanded-collaboration-md-anderson
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005484/en/
Contact information
Media Contacts
Sarah Soetbeer
Boehringer Ingelheim Corporate Center GmbH
Communications + Public Affairs
P: +49 (6132) 77-183874
press@boehringer-ingelheim.com
Linda Ruckel
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
press@boehringer-ingelheim.com
Clayton Boldt, Ph.D.
Public Relations
The University of Texas MD Anderson Cancer Center
P: +1 713-792-9518
crboldt@mdanderson.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DEWA Signs Three Agreements With Global Partners During WETEX 202628.10.2026 16:50:00 EET | Press release
Dubai Electricity and Water Authority (DEWA) signed three agreements with leading global entities during the 28th Water, Energy, Technology and Environment Exhibition (WETEX 2026). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028187355/en/ DEWA signs three agreements with global partners during WETEX 2026 (Photo: AETOSWire) In the presence of HE Saeed Mohammed Al Tayer, MD&CEO of DEWA, the agreements were signed by Hussain Lootah, Executive Vice President of Transmission Power at DEWA, and concluded through Moro Hub, a subsidiary of Digital DEWA, the digital arm of DEWA. Al Tayer said: “We are committed to strengthening our strategic partnerships with leading global organisations and leveraging the latest technologies, solutions and best practices. This enables us to enhance the efficiency, resilience and future-readiness of our critical infrastructure, while keeping pace with advancements in cyber security, digital tra
Ras Al Khaimah Signs Landmark Friendship Agreement & 10 MoUs during Historic High-Level Tour of South China28.10.2026 15:48:00 EET | Press release
His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, witnesses the signing of a historic agreement between Ras Al Khaimah and Fujian Province, China, concluding a six-day China visit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028878989/en/ His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, witnessed the signing of a landmark agreement between Ras Al Khaimah and Fujian Province, alongside 10 Memoranda of Understanding between entities from the Emirate and their Chinese counterparts, reflecting a shared commitment to broadening cooperation and translating longstanding relations into meaningful opportunities for the future. (Photo: AETOSWire) Signed in Fuzhou, the agreement establishes a framework for strengthening economic, maritime and cultural ties, including cooperation in green supply chains, port logistics, sustainabl
Media Release: Further Up – Allianz Reaches Highest-Ever Brand Value of $30.7 Billion28.10.2026 15:08:00 EET | Press release
A steady climb to a new high: For the eighth consecutive year, Allianz is the world’s most valuable insurance brand and has reached a record $30.7 billion in brand value, lifting it one place to No. 26 in Interbrand’s Best Global Brands 2026 ranking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028268225/en/ #1 Global Insurance Brand This 9% increase on 2025 further narrows the gap to the world’s most valuable consumer and tech brands, among them Coca-Cola, Disney and Adobe. The upward trajectory is backed by strong business growth and financial performance as well as a global brand strategy that is built on trust and distinguished with customer relevance and care. Oliver Bäte, Chief Executive Officer of Allianz SE, said: "In a highly competitive brand landscape, we have maintained our momentum by focusing on what matters most to our customers: their health and personal finances. Our strong business fundamentals and con
Seoul Semiconductor Ends Need for Rare Earths in White LEDs28.10.2026 15:03:00 EET | Press release
For three decades, white LEDs have depended on rare earth materials such as yttrium aluminum garnet (YAG) layered onto a blue LED chip (Figure 1). Seoul Viosys Co., Ltd. (KOSDAQ: 092190) today announced that it has broken that dependence. It has developed and begun mass producing a chip that emits white light without rare earths. The chip can be as small as 10 micrometers (µm). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028475699/en/ Figure 1. New invention: white WICOP 3 (source: Seoul Semiconductor Co., Ltd.) Seoul Viosys and its parent company Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890) opened the micro LED market with WICOP. WICOP is a chip architecture that eliminates the package altogether. Doing away with the package is widely regarded in the industry as a revolution in six decades of semiconductor history. With WICOP, the two companies have already developed and mass produced ultraviolet, blue, green, red a
Gurobi’s 2026 State of Mathematical Optimization Report Reveals Growing Convergence of AI and Optimization28.10.2026 15:00:00 EET | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the release of its 2026 State of Mathematical Optimization Report. Based on a survey of 382 non-academic professionals across industries, the report examines how businesses are putting optimization to work, and how its use is evolving alongside other AI technologies. In a notable shift, 79% of respondents now use GenAI or large language models (LLMs) in their optimization work, up from 30% in 2025, with 37% using these tools systematically in their development workflows. Respondents see the greatest potential for this combined approach in code generation and debugging (68%), model formulation (67%), and natural-language interaction with optimization models (62%). Other key findings include: Optimization is becoming part of everyday operations: 52% of respondents say optimization supports ongoing decision-making at their organization, and 45% run it automatically in production workflows. Demand for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom